Marshall Wace
TLX

Marshall Wace’s Telix Pharmaceuticals TLX Stock Holding History

Marshall Wace’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,658
Closed -$349K – 3774
2025
Q4 		$349K Sell
46,658
-1,915
-4% -$18.4K ﹤0.01% 2392
2025
Q3 		$465K Buy
+48,573
New +$595K ﹤0.01% 2259

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Marshall Wace's TLX Position: Q1 2026 in Review

Marshall Wace sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 46,658 shares — an estimated $349K sold.

Marshall Wace first reported a position in TLX in Q3 2025 and held it in 2 quarters. The position peaked at $465K in Q3 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Marshall Wace reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 46,658 Telix Pharmaceuticals shares in Q1 2026, an estimated $349K.
  • Marshall Wace first reported a position in Telix Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Marshall Wace's Telix Pharmaceuticals position peaked at $465K in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.